Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback